American Research & Management Company’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $1.37M | Sell |
31,230
-400
| -1% | -$19.4K | 0.38% | 60 |
|
|
2022
Q2 | $1.66M | Sell |
31,630
-1,475
| -4% | -$75.2K | 0.43% | 59 |
|
|
2022
Q1 | $1.71M | Sell |
33,105
-337
| -1% | -$17.5K | 0.38% | 59 |
|
|
2021
Q4 | $1.98M | Buy |
33,442
+309
| +0.9% | +$15.3K | 0.43% | 58 |
|
|
2021
Q3 | $1.43M | Sell |
33,133
-672
| -2% | -$29.8K | 0.33% | 63 |
|
|
2021
Q2 | $1.32M | Sell |
33,805
-2,922
| -8% | -$114K | 0.3% | 62 |
|
|
2021
Q1 | $1.33M | Hold |
36,727
| – | – | 0.32% | 65 |
|
|
2020
Q4 | $1.35M | Sell |
36,727
-1,878
| -5% | -$68.9K | 0.35% | 63 |
|
|
2020
Q3 | $1.34M | Sell |
38,605
-263
| -0.7% | -$9.22K | 0.39% | 58 |
|
|
2020
Q2 | $1.21M | Sell |
38,868
-396
| -1% | -$13.5K | 0.37% | 60 |
|
|
2020
Q1 | $1.22M | Sell |
39,264
-1,581
| -4% | -$53.9K | 0.46% | 56 |
|
|
2019
Q4 | $1.52M | Sell |
40,845
-8,010
| -16% | -$285K | 0.45% | 55 |
|
|
2019
Q3 | $1.67M | Sell |
48,855
-664
| -1% | -$24.1K | 0.5% | 52 |
|
|
2019
Q2 | $2.04M | Sell |
49,519
-1,533
| -3% | -$60.9K | 0.61% | 47 |
|
|
2019
Q1 | $2.06M | Buy |
51,052
+3,738
| +8% | +$150K | 0.59% | 45 |
|
|
2018
Q4 | $1.96M | Sell |
47,314
-105
| -0.2% | -$4.36K | 0.66% | 44 |
|
|
2018
Q3 | $1.98M | Sell |
47,419
-964
| -2% | -$37.1K | 0.59% | 49 |
|
|
2018
Q2 | $1.67M | Buy |
48,383
+16,612
| +52% | +$568K | 0.58% | 44 |
|
|
2018
Q1 | $1.07M | Sell |
31,771
-416
| -1% | -$14.3K | 0.35% | 61 |
|
|
2017
Q4 | $1.11M | Sell |
32,187
-4,700
| -13% | -$160K | 0.34% | 62 |
|
|
2017
Q3 | $1.25M | Sell |
36,887
-122
| -0.3% | -$3.92K | 0.4% | 60 |
|
|
2017
Q2 | $1.18M | Buy |
37,009
+6
| +0% | +$189 | 0.39% | 59 |
|
|
2017
Q1 | $1.2M | Sell |
37,003
-310
| -0.8% | -$9.77K | 0.43% | 52 |
|
|
2016
Q4 | $1.15M | Buy |
37,313
+8,360
| +29% | +$255K | 0.39% | 55 |
|
|
2016
Q3 | $930K | Sell |
28,953
-1,153
| -4% | -$38.6K | 0.34% | 60 |
|
|
2016
Q2 | $1.01M | Sell |
30,106
-2,486
| -8% | -$79.3K | 0.39% | 61 |
|
|
2016
Q1 | $917K | Sell |
32,592
-199
| -0.6% | -$5.68K | 0.39% | 60 |
|
|
2015
Q4 | $1M | Sell |
32,791
-1,958
| -6% | -$61.6K | 0.43% | 59 |
|
|
2015
Q3 | $1.04M | Sell |
34,749
-418
| -1% | -$13.4K | 0.45% | 59 |
|
|
2015
Q2 | $1.12M | Buy |
35,167
+460
| +1% | +$15K | 0.45% | 58 |
|
|
2015
Q1 | $1.15M | Buy |
34,707
+10
| +0% | +$318 | 0.47% | 56 |
|
|
2014
Q4 | $1.02M | Buy |
34,697
+13
| +0% | +$373 | 0.38% | 63 |
|
|
2014
Q3 | $973K | Sell |
34,684
-410
| -1% | -$11.5K | 0.35% | 63 |
|
|
2014
Q2 | $988K | Sell |
35,094
-726
| -2% | -$20.7K | 0.34% | 64 |
|
|
2014
Q1 | $1.09M | Sell |
35,820
-620
| -2% | -$18.5K | 0.39% | 63 |
|
|
2013
Q4 | $1.06M | Sell |
36,440
-2,410
| -6% | -$70.1K | 0.38% | 65 |
|
|
2013
Q3 | $1.06M | Sell |
38,850
-199
| -0.5% | -$5.42K | 0.42% | 59 |
|
|
2013
Q2 | $1.04M | Buy |
+39,049
| New | +$1.08M | 0.42% | 60 |
|
Other funds holding PFE
American Research & Management Company's PFE Position: Q3 2022 in Review
American Research & Management Company reduced its Pfizer (PFE) stake by 1.3% in Q3 2022, selling an estimated $19.4K and leaving 31,230 shares worth $1.37M. The position accounts for 0.38% of the portfolio, ranked #60.
American Research & Management Company first reported a position in PFE in Q2 2013 and has held it in 38 quarters since. The position peaked at $2.06M in Q1 2019. 3,086 funds tracked by Wall St. Rank hold PFE as of Q3 2022.
- American Research & Management Company held 31,230 shares of Pfizer worth $1.37M as of Q3 2022.
- American Research & Management Company sold 400 Pfizer shares in Q3 2022, an estimated $19.4K.
- Pfizer made up 0.38% of American Research & Management Company's portfolio in Q3 2022, its #60 holding.
- American Research & Management Company first reported a position in Pfizer in Q2 2013 and has held it in 38 quarters since.
- American Research & Management Company's Pfizer position peaked at $2.06M in Q1 2019.
- 3,086 funds tracked by Wall St. Rank held Pfizer as of Q3 2022.
Based on American Research & Management Company's 13F filing for Q3 2022, filed 7 Oct 2022.